ERAXIS

LOE Approaching

anidulafungin

NDAINTRAVENOUSPOWDER
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

anti-fungal drug [see ].

Pharmacologic Class:

Echinocandin Antifungal

Clinical Trials (5)

NCT00802854N/ACompleted

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

Started Mar 2012
244 enrolled
CandidemiaOther Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
NCT01303549Phase 4Completed

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Started Nov 2011
61 enrolled
Liver DiseaseFungal Infection
NCT01202253N/ACompleted

Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Started Feb 2011
50 enrolled
Candidiasis
NCT01176058Phase 3Terminated

A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

Started Dec 2010
17 enrolled
Candidemia
NCT01053884Phase 2Terminated

Anidulafungin in Patients With Hematologic Malignancies

Started Oct 2009
10 enrolled
Hematologic Malignancies